nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—osteoarthritis—Prednisone—Crohn's disease	0.274	1	CpDpCtD
Nabumetone—MPO—Crohn's disease	0.217	0.728	CbGaD
Nabumetone—MPO—Mesalazine—Crohn's disease	0.123	0.359	CbGbCtD
Nabumetone—PTGS2—Crohn's disease	0.0812	0.273	CbGaD
Nabumetone—PTGS2—Balsalazide—Crohn's disease	0.0532	0.155	CbGbCtD
Nabumetone—PTGS1—Balsalazide—Crohn's disease	0.045	0.131	CbGbCtD
Nabumetone—PTGS2—Mesalazine—Crohn's disease	0.0426	0.124	CbGbCtD
Nabumetone—PTGS1—Mesalazine—Crohn's disease	0.0359	0.105	CbGbCtD
Nabumetone—PTGS2—Sulfasalazine—Crohn's disease	0.0238	0.0692	CbGbCtD
Nabumetone—PTGS1—Sulfasalazine—Crohn's disease	0.0201	0.0584	CbGbCtD
Nabumetone—MPO—superior mesenteric artery—Crohn's disease	0.0196	0.7	CbGeAlD
Nabumetone—Eosinophilic pneumonia—Mesalazine—Crohn's disease	0.00207	0.0557	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IL23R—Crohn's disease	0.00133	0.0701	CbGpPWpGaD
Nabumetone—Alveolitis allergic—Mesalazine—Crohn's disease	0.0013	0.035	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IL18RAP—Crohn's disease	0.00127	0.0669	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL23A—Crohn's disease	0.00113	0.0596	CbGpPWpGaD
Nabumetone—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX4—Crohn's disease	0.00105	0.0554	CbGpPWpGaD
Nabumetone—MPO—epithelium—Crohn's disease	0.000793	0.0284	CbGeAlD
Nabumetone—Interstitial pneumonia—Azathioprine—Crohn's disease	0.00077	0.0208	CcSEcCtD
Nabumetone—MPO—skin of body—Crohn's disease	0.000754	0.027	CbGeAlD
Nabumetone—Interstitial pneumonia—Mesalazine—Crohn's disease	0.000701	0.0189	CcSEcCtD
Nabumetone—Nephrotic syndrome—Mesalazine—Crohn's disease	0.000701	0.0189	CcSEcCtD
Nabumetone—Duodenal ulcer—Mesalazine—Crohn's disease	0.000701	0.0189	CcSEcCtD
Nabumetone—PTGS2—gall bladder—Crohn's disease	0.000695	0.0249	CbGeAlD
Nabumetone—Hyperuricaemia—Mercaptopurine—Crohn's disease	0.000673	0.0181	CcSEcCtD
Nabumetone—Blood uric acid increased—Mercaptopurine—Crohn's disease	0.000636	0.0171	CcSEcCtD
Nabumetone—PTGS2—mouth—Crohn's disease	0.000618	0.0221	CbGeAlD
Nabumetone—MPO—lymphoid tissue—Crohn's disease	0.000611	0.0219	CbGeAlD
Nabumetone—MPO—digestive system—Crohn's disease	0.000603	0.0216	CbGeAlD
Nabumetone—MPO—IL23-mediated signaling events—IL17A—Crohn's disease	0.000529	0.0279	CbGpPWpGaD
Nabumetone—Interstitial lung disease—Azathioprine—Crohn's disease	0.000526	0.0142	CcSEcCtD
Nabumetone—Nephritis interstitial—Mesalazine—Crohn's disease	0.000502	0.0135	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IL12B—Crohn's disease	0.000492	0.0259	CbGpPWpGaD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—CREM—Crohn's disease	0.00048	0.0253	CbGpPWpGaD
Nabumetone—Interstitial lung disease—Mesalazine—Crohn's disease	0.000479	0.0129	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—GPX4—Crohn's disease	0.000475	0.025	CbGpPWpGaD
Nabumetone—Albuminuria—Mesalazine—Crohn's disease	0.000454	0.0122	CcSEcCtD
Nabumetone—Tubulointerstitial nephritis—Mesalazine—Crohn's disease	0.000443	0.0119	CcSEcCtD
Nabumetone—Jaundice cholestatic—Azathioprine—Crohn's disease	0.000423	0.0114	CcSEcCtD
Nabumetone—Melatonin—MPO—Crohn's disease	0.000419	0.548	CrCbGaD
Nabumetone—Acne—Mesalazine—Crohn's disease	0.000403	0.0109	CcSEcCtD
Nabumetone—Jaundice cholestatic—Mesalazine—Crohn's disease	0.000386	0.0104	CcSEcCtD
Nabumetone—Pancreatitis—Mercaptopurine—Crohn's disease	0.000384	0.0104	CcSEcCtD
Nabumetone—Vasculitis—Azathioprine—Crohn's disease	0.000381	0.0103	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000377	0.0199	CbGpPWpGaD
Nabumetone—PTGS1—epithelium—Crohn's disease	0.000376	0.0135	CbGeAlD
Nabumetone—Rectal haemorrhage—Mesalazine—Crohn's disease	0.000375	0.0101	CcSEcCtD
Nabumetone—PTGS1—smooth muscle tissue—Crohn's disease	0.000363	0.013	CbGeAlD
Nabumetone—MPO—IL23-mediated signaling events—IL18—Crohn's disease	0.000361	0.019	CbGpPWpGaD
Nabumetone—PTGS2—epithelium—Crohn's disease	0.00036	0.0129	CbGeAlD
Nabumetone—PTGS1—skin of body—Crohn's disease	0.000358	0.0128	CbGeAlD
Nabumetone—Aplastic anaemia—Azathioprine—Crohn's disease	0.000349	0.00942	CcSEcCtD
Nabumetone—PTGS2—smooth muscle tissue—Crohn's disease	0.000347	0.0124	CbGeAlD
Nabumetone—MPO—lymph node—Crohn's disease	0.000345	0.0123	CbGeAlD
Nabumetone—PTGS2—skin of body—Crohn's disease	0.000342	0.0122	CbGeAlD
Nabumetone—Stomatitis—Mercaptopurine—Crohn's disease	0.000341	0.00918	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IKZF1—Crohn's disease	0.000339	0.0179	CbGpPWpGaD
Nabumetone—Eructation—Mesalazine—Crohn's disease	0.000333	0.00898	CcSEcCtD
Nabumetone—Melaena—Mesalazine—Crohn's disease	0.000331	0.00892	CcSEcCtD
Nabumetone—CYP1A2—digestive system—Crohn's disease	0.00033	0.0118	CbGeAlD
Nabumetone—PTGS1—mammalian vulva—Crohn's disease	0.000326	0.0117	CbGeAlD
Nabumetone—Aplastic anaemia—Mesalazine—Crohn's disease	0.000318	0.00858	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CREM—Crohn's disease	0.00031	0.0164	CbGpPWpGaD
Nabumetone—Hepatic failure—Azathioprine—Crohn's disease	0.000301	0.0081	CcSEcCtD
Nabumetone—PTGS1—digestive system—Crohn's disease	0.000286	0.0102	CbGeAlD
Nabumetone—Photosensitivity—Mesalazine—Crohn's disease	0.00028	0.00755	CcSEcCtD
Nabumetone—Gastroenteritis—Mesalazine—Crohn's disease	0.000278	0.00748	CcSEcCtD
Nabumetone—Alopecia—Mercaptopurine—Crohn's disease	0.000277	0.00747	CcSEcCtD
Nabumetone—PTGS2—lymphoid tissue—Crohn's disease	0.000277	0.00991	CbGeAlD
Nabumetone—Hepatic failure—Mesalazine—Crohn's disease	0.000274	0.00738	CcSEcCtD
Nabumetone—PTGS2—digestive system—Crohn's disease	0.000274	0.00979	CbGeAlD
Nabumetone—Peptic ulcer—Prednisone—Crohn's disease	0.000268	0.00723	CcSEcCtD
Nabumetone—Increased appetite—Mesalazine—Crohn's disease	0.000262	0.00706	CcSEcCtD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—Crohn's disease	0.00026	0.0137	CbGpPWpGaD
Nabumetone—Dermatitis bullous—Mesalazine—Crohn's disease	0.000257	0.00694	CcSEcCtD
Nabumetone—Anaemia—Mercaptopurine—Crohn's disease	0.000252	0.0068	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.000246	0.00663	CcSEcCtD
Nabumetone—Leukopenia—Mercaptopurine—Crohn's disease	0.000244	0.00659	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.000243	0.00656	CcSEcCtD
Nabumetone—PTGS1—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000243	0.0128	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—CRP—Crohn's disease	0.000234	0.0123	CbGpPWpGaD
Nabumetone—Pancreatitis—Azathioprine—Crohn's disease	0.000229	0.00617	CcSEcCtD
Nabumetone—Liver function test abnormal—Mesalazine—Crohn's disease	0.000227	0.00612	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—TYK2—Crohn's disease	0.000226	0.0119	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—TAB1—Crohn's disease	0.000225	0.0119	CbGpPWpGaD
Nabumetone—Oedema—Mercaptopurine—Crohn's disease	0.000223	0.00601	CcSEcCtD
Nabumetone—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000218	0.00588	CcSEcCtD
Nabumetone—Gastritis—Mesalazine—Crohn's disease	0.000218	0.00587	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—JAK2—Crohn's disease	0.000216	0.0114	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—ICAM1—Crohn's disease	0.000215	0.0113	CbGpPWpGaD
Nabumetone—Acne—Prednisone—Crohn's disease	0.000213	0.00574	CcSEcCtD
Nabumetone—Asthma—Mesalazine—Crohn's disease	0.000213	0.00573	CcSEcCtD
Nabumetone—Dysphagia—Mesalazine—Crohn's disease	0.000213	0.00573	CcSEcCtD
Nabumetone—Anorexia—Mercaptopurine—Crohn's disease	0.000212	0.00572	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IFNG—Crohn's disease	0.000212	0.0112	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—CRP—Crohn's disease	0.000211	0.0111	CbGpPWpGaD
Nabumetone—Pneumonia—Azathioprine—Crohn's disease	0.000209	0.00564	CcSEcCtD
Nabumetone—Pancreatitis—Mesalazine—Crohn's disease	0.000208	0.00562	CcSEcCtD
Nabumetone—Angina pectoris—Mesalazine—Crohn's disease	0.000207	0.00558	CcSEcCtD
Nabumetone—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—Crohn's disease	0.000207	0.0109	CbGpPWpGaD
Nabumetone—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.000206	0.00556	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—CD4—Crohn's disease	0.000204	0.0108	CbGpPWpGaD
Nabumetone—Dysuria—Mesalazine—Crohn's disease	0.000199	0.00536	CcSEcCtD
Nabumetone—Agranulocytosis—Azathioprine—Crohn's disease	0.000194	0.00524	CcSEcCtD
Nabumetone—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000194	0.00523	CcSEcCtD
Nabumetone—Decreased appetite—Mercaptopurine—Crohn's disease	0.000194	0.00522	CcSEcCtD
Nabumetone—Weight increased—Mesalazine—Crohn's disease	0.000194	0.00522	CcSEcCtD
Nabumetone—PTGS2—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000193	0.0102	CbGpPWpGaD
Nabumetone—Weight decreased—Mesalazine—Crohn's disease	0.000192	0.00519	CcSEcCtD
Nabumetone—Pneumonia—Mesalazine—Crohn's disease	0.000191	0.00514	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—CRP—Crohn's disease	0.00019	0.01	CbGpPWpGaD
Nabumetone—Depression—Mesalazine—Crohn's disease	0.000189	0.0051	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IL1B—Crohn's disease	0.000189	0.00995	CbGpPWpGaD
Nabumetone—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000188	0.00507	CcSEcCtD
Nabumetone—Haemoglobin—Azathioprine—Crohn's disease	0.000188	0.00506	CcSEcCtD
Nabumetone—Haemorrhage—Azathioprine—Crohn's disease	0.000187	0.00504	CcSEcCtD
Nabumetone—Renal failure—Mesalazine—Crohn's disease	0.000186	0.00502	CcSEcCtD
Nabumetone—Jaundice—Mesalazine—Crohn's disease	0.000185	0.00498	CcSEcCtD
Nabumetone—Stomatitis—Mesalazine—Crohn's disease	0.000185	0.00498	CcSEcCtD
Nabumetone—Vasculitis—Prednisone—Crohn's disease	0.000184	0.00495	CcSEcCtD
Nabumetone—Naproxen—PTGS2—Crohn's disease	0.000182	0.239	CrCbGaD
Nabumetone—Haematuria—Mesalazine—Crohn's disease	0.000181	0.00487	CcSEcCtD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—Crohn's disease	0.000181	0.00953	CbGpPWpGaD
Nabumetone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—Crohn's disease	0.000181	0.00952	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—ALB—Crohn's disease	0.000179	0.00945	CbGpPWpGaD
Nabumetone—Agranulocytosis—Mesalazine—Crohn's disease	0.000177	0.00477	CcSEcCtD
Nabumetone—Erythema multiforme—Azathioprine—Crohn's disease	0.000177	0.00476	CcSEcCtD
Nabumetone—Body temperature increased—Mercaptopurine—Crohn's disease	0.000176	0.00475	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—ICAM1—Crohn's disease	0.000175	0.00922	CbGpPWpGaD
Nabumetone—Haemoglobin—Mesalazine—Crohn's disease	0.000171	0.00461	CcSEcCtD
Nabumetone—Haemorrhage—Mesalazine—Crohn's disease	0.00017	0.00459	CcSEcCtD
Nabumetone—Chills—Azathioprine—Crohn's disease	0.000168	0.00452	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—CRP—Crohn's disease	0.000167	0.00883	CbGpPWpGaD
Nabumetone—Arrhythmia—Azathioprine—Crohn's disease	0.000167	0.0045	CcSEcCtD
Nabumetone—Alopecia—Azathioprine—Crohn's disease	0.000165	0.00445	CcSEcCtD
Nabumetone—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000164	0.00442	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—IFNG—Crohn's disease	0.000164	0.00863	CbGpPWpGaD
Nabumetone—PTGS1—lymph node—Crohn's disease	0.000164	0.00585	CbGeAlD
Nabumetone—Naproxen—ALB—Crohn's disease	0.000163	0.213	CrCbGaD
Nabumetone—Erythema multiforme—Mesalazine—Crohn's disease	0.000161	0.00434	CcSEcCtD
Nabumetone—Tinnitus—Mesalazine—Crohn's disease	0.000159	0.00428	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—STAT3—Crohn's disease	0.000158	0.00834	CbGpPWpGaD
Nabumetone—PTGS2—lymph node—Crohn's disease	0.000156	0.00559	CbGeAlD
Nabumetone—PTGS1—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000154	0.00814	CbGpPWpGaD
Nabumetone—Chills—Mesalazine—Crohn's disease	0.000153	0.00412	CcSEcCtD
Nabumetone—Diarrhoea—Mercaptopurine—Crohn's disease	0.000152	0.00411	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—CRP—Crohn's disease	0.000151	0.00797	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Azathioprine—Crohn's disease	0.000151	0.00407	CcSEcCtD
Nabumetone—Alopecia—Mesalazine—Crohn's disease	0.00015	0.00405	CcSEcCtD
Nabumetone—Thrombophlebitis—Prednisone—Crohn's disease	0.00015	0.00405	CcSEcCtD
Nabumetone—Anaemia—Azathioprine—Crohn's disease	0.00015	0.00405	CcSEcCtD
Nabumetone—Malaise—Azathioprine—Crohn's disease	0.000147	0.00395	CcSEcCtD
Nabumetone—Flatulence—Mesalazine—Crohn's disease	0.000146	0.00394	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—IL1B—Crohn's disease	0.000146	0.0077	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—ALB—Crohn's disease	0.000146	0.00769	CbGpPWpGaD
Nabumetone—Leukopenia—Azathioprine—Crohn's disease	0.000146	0.00392	CcSEcCtD
Nabumetone—Tension—Mesalazine—Crohn's disease	0.000145	0.00392	CcSEcCtD
Nabumetone—Nervousness—Mesalazine—Crohn's disease	0.000144	0.00388	CcSEcCtD
Nabumetone—Vomiting—Mercaptopurine—Crohn's disease	0.000142	0.00382	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—PTGS2—Crohn's disease	0.000141	0.00746	CbGpPWpGaD
Nabumetone—Rash—Mercaptopurine—Crohn's disease	0.00014	0.00379	CcSEcCtD
Nabumetone—Dermatitis—Mercaptopurine—Crohn's disease	0.00014	0.00378	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—ICAM1—Crohn's disease	0.000139	0.00733	CbGpPWpGaD
Nabumetone—Tremor—Mesalazine—Crohn's disease	0.000139	0.00374	CcSEcCtD
Nabumetone—Increased appetite—Prednisone—Crohn's disease	0.000139	0.00373	CcSEcCtD
Nabumetone—Ill-defined disorder—Mesalazine—Crohn's disease	0.000137	0.00371	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—CXCL8—Crohn's disease	0.000137	0.00723	CbGpPWpGaD
Nabumetone—Anaemia—Mesalazine—Crohn's disease	0.000137	0.00369	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—TNF—Crohn's disease	0.000137	0.00722	CbGpPWpGaD
Nabumetone—Discomfort—Azathioprine—Crohn's disease	0.000137	0.00369	CcSEcCtD
Nabumetone—Angioedema—Mesalazine—Crohn's disease	0.000135	0.00365	CcSEcCtD
Nabumetone—Malaise—Mesalazine—Crohn's disease	0.000134	0.0036	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IFNG—Crohn's disease	0.000133	0.00702	CbGpPWpGaD
Nabumetone—Vertigo—Mesalazine—Crohn's disease	0.000133	0.00359	CcSEcCtD
Nabumetone—Syncope—Mesalazine—Crohn's disease	0.000133	0.00358	CcSEcCtD
Nabumetone—Leukopenia—Mesalazine—Crohn's disease	0.000133	0.00358	CcSEcCtD
Nabumetone—Nausea—Mercaptopurine—Crohn's disease	0.000132	0.00357	CcSEcCtD
Nabumetone—Palpitations—Mesalazine—Crohn's disease	0.000131	0.00353	CcSEcCtD
Nabumetone—Loss of consciousness—Mesalazine—Crohn's disease	0.00013	0.00351	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.00013	0.00351	CcSEcCtD
Nabumetone—Thrombocytopenia—Azathioprine—Crohn's disease	0.00013	0.0035	CcSEcCtD
Nabumetone—Cough—Mesalazine—Crohn's disease	0.000129	0.00349	CcSEcCtD
Nabumetone—Hypertension—Mesalazine—Crohn's disease	0.000128	0.00345	CcSEcCtD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—Crohn's disease	0.000127	0.00667	CbGpPWpGaD
Nabumetone—Anxiety—Mesalazine—Crohn's disease	0.000126	0.00339	CcSEcCtD
Nabumetone—Discomfort—Mesalazine—Crohn's disease	0.000125	0.00336	CcSEcCtD
Nabumetone—Dry mouth—Mesalazine—Crohn's disease	0.000123	0.00333	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—GPX4—Crohn's disease	0.000123	0.00646	CbGpPWpGaD
Nabumetone—Confusional state—Mesalazine—Crohn's disease	0.000122	0.00329	CcSEcCtD
Nabumetone—Anaphylactic shock—Mesalazine—Crohn's disease	0.000121	0.00326	CcSEcCtD
Nabumetone—Oedema—Mesalazine—Crohn's disease	0.000121	0.00326	CcSEcCtD
Nabumetone—Shock—Mesalazine—Crohn's disease	0.000119	0.00321	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL1B—Crohn's disease	0.000119	0.00626	CbGpPWpGaD
Nabumetone—Hypokalaemia—Prednisone—Crohn's disease	0.000118	0.00319	CcSEcCtD
Nabumetone—Thrombocytopenia—Mesalazine—Crohn's disease	0.000118	0.00319	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—MPO—Crohn's disease	0.000118	0.0062	CbGpPWpGaD
Nabumetone—PTGS1—Eicosanoid Synthesis—PTGS2—Crohn's disease	0.000117	0.00619	CbGpPWpGaD
Nabumetone—Hyperhidrosis—Mesalazine—Crohn's disease	0.000117	0.00315	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—Crohn's disease	0.000117	0.00616	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—ALB—Crohn's disease	0.000116	0.00611	CbGpPWpGaD
Nabumetone—Anorexia—Mesalazine—Crohn's disease	0.000115	0.00311	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IL6—Crohn's disease	0.000111	0.00582	CbGpPWpGaD
Nabumetone—Pancreatitis—Prednisone—Crohn's disease	0.00011	0.00297	CcSEcCtD
Nabumetone—Sweating increased—Prednisone—Crohn's disease	0.00011	0.00295	CcSEcCtD
Nabumetone—Feeling abnormal—Azathioprine—Crohn's disease	0.000109	0.00295	CcSEcCtD
Nabumetone—Insomnia—Mesalazine—Crohn's disease	0.000109	0.00295	CcSEcCtD
Nabumetone—CYP1A2—Arachidonic acid metabolism—GPX4—Crohn's disease	0.000109	0.00574	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—CXCL8—Crohn's disease	0.000109	0.00574	CbGpPWpGaD
Nabumetone—Paraesthesia—Mesalazine—Crohn's disease	0.000109	0.00293	CcSEcCtD
Nabumetone—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000109	0.00293	CcSEcCtD
Nabumetone—Dyspnoea—Mesalazine—Crohn's disease	0.000108	0.00291	CcSEcCtD
Nabumetone—Somnolence—Mesalazine—Crohn's disease	0.000108	0.0029	CcSEcCtD
Nabumetone—Dyspepsia—Mesalazine—Crohn's disease	0.000106	0.00287	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—CD4—Crohn's disease	0.000106	0.00559	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—TNF—Crohn's disease	0.000106	0.00558	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—IFNG—Crohn's disease	0.000106	0.00558	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—PTGS2—Crohn's disease	0.000105	0.00555	CbGpPWpGaD
Nabumetone—Decreased appetite—Mesalazine—Crohn's disease	0.000105	0.00283	CcSEcCtD
Nabumetone—Abdominal pain—Azathioprine—Crohn's disease	0.000105	0.00283	CcSEcCtD
Nabumetone—Body temperature increased—Azathioprine—Crohn's disease	0.000105	0.00283	CcSEcCtD
Nabumetone—Fatigue—Mesalazine—Crohn's disease	0.000104	0.00281	CcSEcCtD
Nabumetone—Erectile dysfunction—Prednisone—Crohn's disease	0.000104	0.00279	CcSEcCtD
Nabumetone—Constipation—Mesalazine—Crohn's disease	0.000103	0.00279	CcSEcCtD
Nabumetone—Weight increased—Prednisone—Crohn's disease	0.000102	0.00276	CcSEcCtD
Nabumetone—Weight decreased—Prednisone—Crohn's disease	0.000102	0.00274	CcSEcCtD
Nabumetone—Hyperglycaemia—Prednisone—Crohn's disease	0.000101	0.00274	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—PTGS2—Crohn's disease	0.000101	0.00535	CbGpPWpGaD
Nabumetone—Depression—Prednisone—Crohn's disease	0.0001	0.0027	CcSEcCtD
Nabumetone—Feeling abnormal—Mesalazine—Crohn's disease	9.97e-05	0.00269	CcSEcCtD
Nabumetone—Acute coronary syndrome—Prednisone—Crohn's disease	9.89e-05	0.00267	CcSEcCtD
Nabumetone—Gastrointestinal pain—Mesalazine—Crohn's disease	9.89e-05	0.00267	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MST1—Crohn's disease	9.88e-05	0.00521	CbGpPWpGaD
Nabumetone—Myocardial infarction—Prednisone—Crohn's disease	9.83e-05	0.00265	CcSEcCtD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—Crohn's disease	9.82e-05	0.00517	CbGpPWpGaD
Nabumetone—Hypersensitivity—Azathioprine—Crohn's disease	9.78e-05	0.00264	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—MPO—Crohn's disease	9.7e-05	0.00511	CbGpPWpGaD
Nabumetone—Urticaria—Mesalazine—Crohn's disease	9.61e-05	0.00259	CcSEcCtD
Nabumetone—Abdominal pain—Mesalazine—Crohn's disease	9.56e-05	0.00258	CcSEcCtD
Nabumetone—Body temperature increased—Mesalazine—Crohn's disease	9.56e-05	0.00258	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—TNF—Crohn's disease	9.55e-05	0.00503	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—IL1B—Crohn's disease	9.44e-05	0.00497	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—MPO—Crohn's disease	9.34e-05	0.00492	CbGpPWpGaD
Nabumetone—Diarrhoea—Azathioprine—Crohn's disease	9.08e-05	0.00245	CcSEcCtD
Nabumetone—Haemoglobin—Prednisone—Crohn's disease	9.05e-05	0.00244	CcSEcCtD
Nabumetone—Haemorrhage—Prednisone—Crohn's disease	9.01e-05	0.00243	CcSEcCtD
Nabumetone—Hypersensitivity—Mesalazine—Crohn's disease	8.91e-05	0.0024	CcSEcCtD
Nabumetone—Dizziness—Azathioprine—Crohn's disease	8.78e-05	0.00237	CcSEcCtD
Nabumetone—Asthenia—Mesalazine—Crohn's disease	8.68e-05	0.00234	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—TNF—Crohn's disease	8.62e-05	0.00454	CbGpPWpGaD
Nabumetone—Pruritus—Mesalazine—Crohn's disease	8.56e-05	0.00231	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—IL6—Crohn's disease	8.55e-05	0.00451	CbGpPWpGaD
Nabumetone—Vomiting—Azathioprine—Crohn's disease	8.44e-05	0.00228	CcSEcCtD
Nabumetone—Rash—Azathioprine—Crohn's disease	8.37e-05	0.00226	CcSEcCtD
Nabumetone—Dermatitis—Azathioprine—Crohn's disease	8.36e-05	0.00225	CcSEcCtD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—Crohn's disease	8.35e-05	0.0044	CbGpPWpGaD
Nabumetone—Headache—Azathioprine—Crohn's disease	8.32e-05	0.00224	CcSEcCtD
Nabumetone—Diarrhoea—Mesalazine—Crohn's disease	8.27e-05	0.00223	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Crohn's disease	8.19e-05	0.00432	CbGpPWpGaD
Nabumetone—Arrhythmia—Prednisone—Crohn's disease	8.05e-05	0.00217	CcSEcCtD
Nabumetone—Dizziness—Mesalazine—Crohn's disease	8e-05	0.00216	CcSEcCtD
Nabumetone—Alopecia—Prednisone—Crohn's disease	7.96e-05	0.00215	CcSEcCtD
Nabumetone—Nausea—Azathioprine—Crohn's disease	7.89e-05	0.00213	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—IL6—Crohn's disease	7.71e-05	0.00406	CbGpPWpGaD
Nabumetone—Vomiting—Mesalazine—Crohn's disease	7.69e-05	0.00207	CcSEcCtD
Nabumetone—Rash—Mesalazine—Crohn's disease	7.62e-05	0.00206	CcSEcCtD
Nabumetone—Dermatitis—Mesalazine—Crohn's disease	7.62e-05	0.00205	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—Crohn's disease	7.6e-05	0.00401	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—TNF—Crohn's disease	7.58e-05	0.004	CbGpPWpGaD
Nabumetone—Headache—Mesalazine—Crohn's disease	7.58e-05	0.00204	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—TAB1—Crohn's disease	7.3e-05	0.00385	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Prednisone—Crohn's disease	7.27e-05	0.00196	CcSEcCtD
Nabumetone—Anaemia—Prednisone—Crohn's disease	7.25e-05	0.00195	CcSEcCtD
Nabumetone—Agitation—Prednisone—Crohn's disease	7.2e-05	0.00194	CcSEcCtD
Nabumetone—Nausea—Mesalazine—Crohn's disease	7.18e-05	0.00194	CcSEcCtD
Nabumetone—Angioedema—Prednisone—Crohn's disease	7.16e-05	0.00193	CcSEcCtD
Nabumetone—Malaise—Prednisone—Crohn's disease	7.07e-05	0.00191	CcSEcCtD
Nabumetone—Vertigo—Prednisone—Crohn's disease	7.04e-05	0.0019	CcSEcCtD
Nabumetone—Syncope—Prednisone—Crohn's disease	7.03e-05	0.0019	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL6—Crohn's disease	6.95e-05	0.00367	CbGpPWpGaD
Nabumetone—Loss of consciousness—Prednisone—Crohn's disease	6.89e-05	0.00186	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—TNF—Crohn's disease	6.85e-05	0.00361	CbGpPWpGaD
Nabumetone—Hypertension—Prednisone—Crohn's disease	6.77e-05	0.00182	CcSEcCtD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—STAT3—Crohn's disease	6.72e-05	0.00354	CbGpPWpGaD
Nabumetone—Anxiety—Prednisone—Crohn's disease	6.65e-05	0.00179	CcSEcCtD
Nabumetone—Discomfort—Prednisone—Crohn's disease	6.59e-05	0.00178	CcSEcCtD
Nabumetone—PTGS1—Arachidonic acid metabolism—PTGS2—Crohn's disease	6.52e-05	0.00344	CbGpPWpGaD
Nabumetone—Oedema—Prednisone—Crohn's disease	6.4e-05	0.00172	CcSEcCtD
Nabumetone—Anaphylactic shock—Prednisone—Crohn's disease	6.4e-05	0.00172	CcSEcCtD
Nabumetone—Shock—Prednisone—Crohn's disease	6.29e-05	0.0017	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—CRP—Crohn's disease	6.19e-05	0.00326	CbGpPWpGaD
Nabumetone—Hyperhidrosis—Prednisone—Crohn's disease	6.19e-05	0.00167	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—IL6—Crohn's disease	6.12e-05	0.00323	CbGpPWpGaD
Nabumetone—Anorexia—Prednisone—Crohn's disease	6.1e-05	0.00164	CcSEcCtD
Nabumetone—Insomnia—Prednisone—Crohn's disease	5.79e-05	0.00156	CcSEcCtD
Nabumetone—Paraesthesia—Prednisone—Crohn's disease	5.75e-05	0.00155	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—ICAM1—Crohn's disease	5.69e-05	0.003	CbGpPWpGaD
Nabumetone—Dyspepsia—Prednisone—Crohn's disease	5.63e-05	0.00152	CcSEcCtD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	5.59e-05	0.00295	CbGpPWpGaD
Nabumetone—Decreased appetite—Prednisone—Crohn's disease	5.56e-05	0.0015	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—IL6—Crohn's disease	5.53e-05	0.00291	CbGpPWpGaD
Nabumetone—Fatigue—Prednisone—Crohn's disease	5.52e-05	0.00149	CcSEcCtD
Nabumetone—Constipation—Prednisone—Crohn's disease	5.47e-05	0.00147	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Crohn's disease	5.4e-05	0.00285	CbGpPWpGaD
Nabumetone—Feeling abnormal—Prednisone—Crohn's disease	5.27e-05	0.00142	CcSEcCtD
Nabumetone—Gastrointestinal pain—Prednisone—Crohn's disease	5.23e-05	0.00141	CcSEcCtD
Nabumetone—Urticaria—Prednisone—Crohn's disease	5.08e-05	0.00137	CcSEcCtD
Nabumetone—Body temperature increased—Prednisone—Crohn's disease	5.06e-05	0.00136	CcSEcCtD
Nabumetone—Abdominal pain—Prednisone—Crohn's disease	5.06e-05	0.00136	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—Crohn's disease	5.02e-05	0.00265	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—CRP—Crohn's disease	4.91e-05	0.00259	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	4.75e-05	0.00251	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—ALB—Crohn's disease	4.74e-05	0.0025	CbGpPWpGaD
Nabumetone—Hypersensitivity—Prednisone—Crohn's disease	4.71e-05	0.00127	CcSEcCtD
Nabumetone—Asthenia—Prednisone—Crohn's disease	4.59e-05	0.00124	CcSEcCtD
Nabumetone—Pruritus—Prednisone—Crohn's disease	4.53e-05	0.00122	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—ICAM1—Crohn's disease	4.52e-05	0.00238	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	4.44e-05	0.00234	CbGpPWpGaD
Nabumetone—Diarrhoea—Prednisone—Crohn's disease	4.38e-05	0.00118	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—IFNG—Crohn's disease	4.33e-05	0.00228	CbGpPWpGaD
Nabumetone—Dizziness—Prednisone—Crohn's disease	4.23e-05	0.00114	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—PTGS2—Crohn's disease	4.15e-05	0.00219	CbGpPWpGaD
Nabumetone—Vomiting—Prednisone—Crohn's disease	4.07e-05	0.0011	CcSEcCtD
Nabumetone—Rash—Prednisone—Crohn's disease	4.03e-05	0.00109	CcSEcCtD
Nabumetone—Dermatitis—Prednisone—Crohn's disease	4.03e-05	0.00109	CcSEcCtD
Nabumetone—Headache—Prednisone—Crohn's disease	4.01e-05	0.00108	CcSEcCtD
Nabumetone—CYP1A2—Metapathway biotransformation—GPX4—Crohn's disease	4e-05	0.00211	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	4e-05	0.00211	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL1B—Crohn's disease	3.86e-05	0.00204	CbGpPWpGaD
Nabumetone—Nausea—Prednisone—Crohn's disease	3.8e-05	0.00102	CcSEcCtD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	3.77e-05	0.00199	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—ALB—Crohn's disease	3.77e-05	0.00199	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	3.74e-05	0.00197	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TLR4—Crohn's disease	3.73e-05	0.00196	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	3.7e-05	0.00195	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—ICAM1—Crohn's disease	3.57e-05	0.00188	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Crohn's disease	3.5e-05	0.00184	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	3.47e-05	0.00183	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CD4—Crohn's disease	3.44e-05	0.00182	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IFNG—Crohn's disease	3.44e-05	0.00181	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	3.27e-05	0.00172	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	3.13e-05	0.00165	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL1B—Crohn's disease	3.07e-05	0.00162	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	2.94e-05	0.00155	CbGpPWpGaD
Nabumetone—CYP1A2—Arachidonic acid metabolism—PTGS2—Crohn's disease	2.93e-05	0.00154	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	2.91e-05	0.00154	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—TNF—Crohn's disease	2.8e-05	0.00148	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	2.75e-05	0.00145	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IFNG—Crohn's disease	2.72e-05	0.00143	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CXCL8—Crohn's disease	2.53e-05	0.00133	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	2.51e-05	0.00132	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PLA2G4F—Crohn's disease	2.49e-05	0.00131	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL1B—Crohn's disease	2.42e-05	0.00128	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL6—Crohn's disease	2.26e-05	0.00119	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—TNF—Crohn's disease	2.22e-05	0.00117	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	2.14e-05	0.00113	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—MTMR3—Crohn's disease	2.12e-05	0.00112	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	2.12e-05	0.00111	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	2.12e-05	0.00111	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RSPO3—Crohn's disease	2.06e-05	0.00109	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PLA2G4F—Crohn's disease	1.98e-05	0.00104	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SEL1L—Crohn's disease	1.96e-05	0.00103	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL6—Crohn's disease	1.8e-05	0.000946	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TNF—Crohn's disease	1.76e-05	0.000927	CbGpPWpGaD
Nabumetone—PTGS2—Disease—LTF—Crohn's disease	1.75e-05	0.000924	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—MTMR3—Crohn's disease	1.68e-05	0.000886	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	1.66e-05	0.000877	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—FADS1—Crohn's disease	1.65e-05	0.000869	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	1.56e-05	0.000821	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GPX4—Crohn's disease	1.54e-05	0.000814	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GCKR—Crohn's disease	1.49e-05	0.000786	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL6—Crohn's disease	1.42e-05	0.000748	CbGpPWpGaD
Nabumetone—PTGS2—Disease—GCKR—Crohn's disease	1.41e-05	0.000745	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—FADS1—Crohn's disease	1.31e-05	0.00069	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SLC11A1—Crohn's disease	1.25e-05	0.000659	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GPX4—Crohn's disease	1.23e-05	0.000646	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	1.2e-05	0.000631	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GCKR—Crohn's disease	1.18e-05	0.000624	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	1.12e-05	0.000589	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RBX1—Crohn's disease	1.07e-05	0.000565	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HSPA1B—Crohn's disease	1.07e-05	0.000565	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.07e-05	0.000562	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—MTMR3—Crohn's disease	9.51e-06	0.000501	CbGpPWpGaD
Nabumetone—PTGS2—Disease—UBE2D1—Crohn's disease	9.39e-06	0.000495	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	9.32e-06	0.000491	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	8.46e-06	0.000446	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—FADS1—Crohn's disease	7.41e-06	0.00039	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GPX4—Crohn's disease	6.94e-06	0.000366	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SMAD3—Crohn's disease	6.72e-06	0.000354	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GCKR—Crohn's disease	6.7e-06	0.000353	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	4.79e-06	0.000252	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ALB—Crohn's disease	4.75e-06	0.00025	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TYK2—Crohn's disease	4.38e-06	0.000231	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.19e-06	0.000221	CbGpPWpGaD
Nabumetone—PTGS2—Disease—JAK2—Crohn's disease	4.18e-06	0.00022	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTGS2—Crohn's disease	4.15e-06	0.000219	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CD4—Crohn's disease	3.97e-06	0.000209	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ALB—Crohn's disease	3.77e-06	0.000199	CbGpPWpGaD
Nabumetone—PTGS2—Disease—STAT3—Crohn's disease	3.07e-06	0.000162	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IL6—Crohn's disease	2.14e-06	0.000113	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ALB—Crohn's disease	2.13e-06	0.000112	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS2—Crohn's disease	1.87e-06	9.83e-05	CbGpPWpGaD
